全文获取类型
收费全文 | 19981篇 |
免费 | 1776篇 |
国内免费 | 253篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 1952篇 |
妇产科学 | 2943篇 |
基础医学 | 1667篇 |
口腔科学 | 202篇 |
临床医学 | 1741篇 |
内科学 | 2158篇 |
皮肤病学 | 65篇 |
神经病学 | 1013篇 |
特种医学 | 273篇 |
外科学 | 1225篇 |
综合类 | 1990篇 |
一般理论 | 4篇 |
预防医学 | 3852篇 |
眼科学 | 127篇 |
药学 | 1884篇 |
7篇 | |
中国医学 | 465篇 |
肿瘤学 | 410篇 |
出版年
2023年 | 403篇 |
2022年 | 408篇 |
2021年 | 760篇 |
2020年 | 776篇 |
2019年 | 876篇 |
2018年 | 778篇 |
2017年 | 887篇 |
2016年 | 820篇 |
2015年 | 759篇 |
2014年 | 1309篇 |
2013年 | 1766篇 |
2012年 | 1069篇 |
2011年 | 1267篇 |
2010年 | 1004篇 |
2009年 | 981篇 |
2008年 | 1009篇 |
2007年 | 962篇 |
2006年 | 808篇 |
2005年 | 709篇 |
2004年 | 605篇 |
2003年 | 517篇 |
2002年 | 394篇 |
2001年 | 333篇 |
2000年 | 278篇 |
1999年 | 228篇 |
1998年 | 174篇 |
1997年 | 139篇 |
1996年 | 139篇 |
1995年 | 135篇 |
1994年 | 137篇 |
1993年 | 123篇 |
1992年 | 107篇 |
1991年 | 107篇 |
1990年 | 95篇 |
1989年 | 70篇 |
1988年 | 85篇 |
1987年 | 67篇 |
1986年 | 73篇 |
1985年 | 126篇 |
1984年 | 122篇 |
1983年 | 88篇 |
1982年 | 75篇 |
1981年 | 69篇 |
1980年 | 73篇 |
1979年 | 65篇 |
1978年 | 54篇 |
1977年 | 35篇 |
1976年 | 36篇 |
1975年 | 22篇 |
1973年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Lucia Taramasso Paolo Bonfanti Elena Ricci Paolo Maggi Giancarlo Orofino Nicola Squillace Barbara Menzaghi Giordano Madeddu Chiara Molteni Francesca Vichi Erika Riguccini Annalisa Saracino Carmen Santoro Marta Guastavigna Daniela Francisci Antonio Di Biagio Giuseppe Vittorio De Socio 《HIV medicine》2022,23(1):70-79
2.
《Mayo Clinic proceedings. Mayo Clinic》2022,97(7):1237-1246
ObjectiveTo determine the long-term cardiovascular disease risk of astronauts with spaceflight exposure compared with a well-matched cohort.MethodsNational Aeronautics and Space Administration (NASA) astronauts are selected into their profession based upon education, unique skills, and health and are exposed to cardiovascular disease risk factors during spaceflight. The Cooper Center Longitudinal Study (CCLS) is a generally healthy cohort from a preventive medicine clinic in Dallas, Texas. Using a matched cohort design, astronauts who were selected beginning April 1, 1959, (and each subsequent selection class through 2009) and exposed to spaceflight were matched to CCLS participants who met astronaut selection criteria; 1514 CCLS participants matched to 303 astronauts in a 5-to-1 ratio on sex, date of birth, and age. The outcome of cardiovascular mortality through December 31, 2016, was determined by death certificate or National Death Index.ResultsThere were 11 deaths caused by cardiovascular disease (CVD) among astronauts and 46 among CCLS participants. There was no evidence of increased mortality risk in astronauts (hazard ratio [HR]=1.10; 95% confidence interval [CI], 0.50 to 2.45) with adjustment for baseline cardiovascular covariates. However, the secondary outcome of CVD events showed an increased adjusted risk in astronauts (HR=2.41; 95% CI, 1.26 to 4.63).ConclusionNo increased risk of CVD mortality was observed in astronauts with spaceflight exposure compared with a well-matched cohort, but there was evidence of increased total CVD events. Given that the duration of spaceflight will increase, particularly on missions to Mars, continued surveillance and mitigation of CVD risk is needed to ensure the safety of those who venture into space. 相似文献
3.
目的分析低分子肝素钙抗凝对多囊卵巢综合征(PCOS)所致不孕症患者来曲唑诱导排卵疗效的影响。方法选取2014年1月—2019年1月九江市第三人民医院和彭泽县妇幼保健院收治的156例PCOS所致不孕症患者,采用随机数字表分成两组,每组78例。对照组口服来曲唑治疗,观察组采取口服来曲唑联合低分子肝素钙注射液治疗。比较两组的疗效、子宫内膜容受性、凝血功能指标、促排卵结局及不良反应。结果观察组总有效率[94.87%(74/78)]显著高于对照组[80.77%(63/78)],差异有统计学意义(χ2=7.252,P=0.007)。治疗后,观察组子宫内膜厚度、子宫动脉搏动指数(PI)及阻力指数(RI)分别为(9.75±1.03)mm、(1.30±0.26)及(0.58±0.12),对照组子宫内膜厚度、PI及RI分别为(7.48±0.95)mm、(1.71±0.33)及(0.66±0.11),两组比较差异均有统计学意义(t=14.308,8.619,4.340,均P<0.05)。治疗后,两组凝血功能指标比较差异均有统计学意义(均P<0.05)。观察组妊娠率[52.56%(41/78)]显著高于对照组[32.05%(25/78)],自然流产率[2.44%(1/41)]显著低于对照组[16.00%(4/25)],差异均有统计学意义(均P<0.05)。观察组不良反应发生率[16.67%(13/78)]与对照组[12.82%(10/78)]比较差异无统计学意义(χ2=0.459,P=0.498)。结论PCOS所致不孕症患者在应用来曲唑诱导排卵的同时联合低分子肝素钙抗凝治疗能有效改善患者的凝血-纤溶状态,明显提高患者的子宫内膜容受性,改善促排卵结局。 相似文献
4.
Keith B. Diamond Ivan J. Golub Asad M. Ashraf Samuel J. Swiggett Paul V. Romeo Jack Choueka 《Seminars in Arthroplasty》2022,32(1):15-22
BackgroundWhile studies have demonstrated favorable outcomes in utilization of primary total shoulder arthroplasty (TSA) for the treatment of glenohumeral osteoarthritis (OA), adverse events such as infections can still occur. Periprosthetic joint infections (PJIs) are associated with worse outcomes and patient morbidity. The purpose of this study was to: (1) compare patient demographics amongst TSA patients with and without PJIs following primary TSA; and (2) identify patient-related risk factors for PJIs following primary TSA.MethodsPatients undergoing primary TSA for the treatment of glenohumeral OA were identified using the Mariner administrative claims database by CPT code 23,472. Laterality modifiers were utilized to ensure PJIs were developing in the correct laterality as those patients undergoing primary TSA. Inclusion for the study group consisted of patients who developed PJIs within 2-years after the index procedure, whereas patients who did not develop PJIs served as the comparison cohort. Primary outcomes analyzed included patient demographics and patient-related risk factors for PJIs following primary TSA. A stepwise backwards elimination multivariate binomial logistic regression analyses was performed to determine the odds (OR) of PJIs in patients undergoing primary TSA. A P value less than .05 was considered statistically significant.ResultsThe query yielded 15,396 patients who underwent primary TSA for glenohumeral OA, of which 191 patients developed PJIs and 15,205 did not develop PJIs. The study found statistically significant differences amongst patients who did and did not develop PJIs following primary TSA with respect to age, sex, and presence of comorbid conditions. Risk factors associated with developing PJIs following primary TSA included: pathologic weight loss (OR: 2.06, P < .0001), obesity (OR: 1.56, P = .0001), male sex (OR: 1.52, P = .007), and peripheral vascular disease (OR: 1.46, P = .022).ConclusionAs the number of primary TSAs for the treatment of glenohumeral OA increase worldwide, identifying modifiable risk-factors to reduce the incidence of infection is critical. The study found various modifiable and non-modifiable risk factors associated with developing PJIs following primary TSA. This study is valuable to orthopedists in order to identify and risk-stratify patients with regard to PJI in the setting of primary TSA for OA.Level of EvidenceLevel III; Case-Control Study 相似文献
5.
Francesca Bodega Anita Russi Francesco Melillo Fabiana Blunda Claudia Rubino Giulio Leo Alberto Cappelletti Patrizio Mazzone Paolo Mattiello Paolo Della Bella Alessandro Castiglioni Ottavio Alfieri Michele De Bonis Matteo Montorfano Moreno Tresoldi Massimo Filippi Anna Salerno Michela Cera Alberto Zangrillo Margonato Alberto Cosmo Godino 《European journal of clinical investigation》2022,52(1):e13658
6.
《Vaccine》2022,40(6):904-911
BackgroundGSK initiated a Pregnancy Registry in the United States (US) for the reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap; Boostrix, GSK) vaccine with the aim to detect and describe pregnancy outcomes in women vaccinated with Boostrix 28 days before estimated conception or during pregnancy.MethodsVoluntary reports of pregnancy exposure to Boostrix received from spontaneous and post-marketing surveillance sources in the US were assessed. Reports were classified as prospective or retrospective based on the knowledge of pregnancy outcomes at the time of reporting. For completeness, reports of exposure to Boostrix or to the Tdap-inactivated poliovirus vaccine (Boostrix-IPV, GSK) reported to the global safety database from countries outside the US were also evaluated.ResultsFrom May 2005 to August 2019, 1517 (1455 prospective and 62 retrospective) pregnancy reports were received in the Boostrix US Pregnancy Registry. Of the prospective reports, 250 had known outcomes: 244 live infants with no apparent birth defects (BDs), three live infants with BDs, and three spontaneous abortions with no apparent BDs. Of the retrospective reports, 55 had known outcomes: 33 live infants with no apparent BDs, 16 live infants with BDs, one spontaneous abortion with no apparent BDs, four stillbirths with no apparent BDs, and one stillbirth with BDs. Cumulatively, 1321 pregnancy reports (1006 for Boostrix; 315 for Boostrix-IPV) were received from countries outside the US. Of these, 163 prospective reports and 551 retrospective reports had known outcomes. Results were in line with those from the Boostrix US Pregnancy Registry.ConclusionsData currently available from the Boostrix US Pregnancy Registry and from countries outside the US suggested that exposure to Boostrix or Boostrix-IPV during pregnancy does not raise safety concerns related to adverse pregnancy outcomes or BDs. 相似文献
7.
目的:探讨袋鼠式护理对使用无创呼吸机早产儿住院期间母乳喂养、喂养不耐受、体质量增长速率及住院费用的影响。方法:选取2019年8月至2020年8月入住NICU的早产儿为研究对象,随机分为干预组(30例)和对照组(30例)。对照组实施常规早产儿发育支持护理,干预组在常规发育支持护理的基础上实施袋鼠式护理。结果:干预组早产儿母乳喂养比例及纯母乳喂养率高于对照组,喂养不耐受发生率低于对照组,体质量增长速率高于对照组,住院时间短于对照组,住院费用低于对照组,差异均有统计学意义(P<0.05)。结论:袋鼠式护理可提高使用无创呼吸机早产儿住院期间的母乳喂养比例及纯母乳喂养率,降低使用无创呼吸机早产儿喂养不耐受发生率,提高恢复至出生体质量速率,缩短住院时间,节省住院费用。 相似文献
8.
目的探讨低分子量肝素在子痫前期患者中的应用效果。方法回顾性调查我院2019年1~4月290例子痫前期患者,根据产后1 d采用的治疗方法分为肝素组(190例)及对照组(100例),分析比较两组的一般资料和凝血指标差异。结果肝素组的新生儿体重和Apgar评分(1 min)低于对照组(P<0.05)。肝素组与对照组在产前仅凝血酶时间、D-二聚体、血小板体积分布宽度有差异,产后1 d肝素组纤维蛋白原含量、血小板计数、血小板压积低于对照组,凝血酶时间、D-二聚体、血小板体积分布宽度高于对照组(P<0.05)。产后3 d仅D-二聚体有差异。结论在产后1 d应用低分子量肝素有助于子痫前期患者产后凝血状态向正常恢复。 相似文献
9.
新生儿重症监护病房中早产儿的侵袭性真菌感染(invasive fungal infection,IFI)发生率较高,且早期临床诊断困难,一旦发生,病情重,疗程长,花费高,病死率较高,预后差。因此预防IFI尤为重要。目前临床常选氟康唑作为预防早产儿IFI的一线药物,但具体剂量、疗程尚不统一,使用对象及预防效果也存在争议。该文对近年来新生儿重症监护病房中药物预防早产儿IFI的研究进展进行综述,供临床医生参考。 相似文献
10.
美国心脏协会在Circulation杂志上发布了2021年促进心血管健康膳食指南。在这一最新的膳食指南中提出控制能量平衡、保持健康体质量、增加水果蔬菜的摄入、偏向选择全谷物食品、减少精加工食品的摄入、避免摄入超加工食品、合理使用植物油、尽量减少含糖食物、选择低盐饮食、合理控制饮酒等建议,对保护心血管系统具有重要的意义。本文针对这一最新的膳食指南进行解读,并结合东方饮食习惯以及近年来中国人群膳食习惯的改变,提出切合中国人群的健康膳食建议。 相似文献